The assisted reproductive technology market size is estimated to be USD 24,857.1 million in 2022 and is expected to witness a CAGR of 6.51% during the forecast period 2023-2033. Growing infertility rates, increasing ART success rates, and rising disposable income in developing nations are projected to drive the market growth in near future. Furthermore, technological development, new product launches, and strategic mergers and acquisitions by key players is projected to support the market growth. However, rising price of assisted reproductive technology are predicted to limit market growth are expected to restrain the market growth.

Technological development, new product launches, and strategic mergers and acquisitions by key players is projected to support the market growth during the projected period. For instance, Generate Life Sciences was fully acquired by CooperCompanies in December 2021. The primary source of donor sperm and eggs for use in fertility treatments is Generate Life Sciences. The 1.6 billion USD purchase is anticipated to benefit CooperCompanies’ fertility services.

Rising acceptance ART is estimated to fuel the market growth during the forecast period. The demand for ART operations is anticipated to increase as society accepts ART more and more as a result of the use of more advanced software including time-lapse embryo imaging and pre-implantation genetic testing. For instance, the Centers for Disease Control and Prevention (CDC) 2019 Fertility Clinic Success Rates Report reveals that 448 fertility clinics in the U.S. conducted approximately 330,773 ART treatments, leading to 77,998 live births and 83,946 live-born babies.Additionally, the sector is anticipated to develop as public knowledge of the factors that contribute to infertility and its treatments increases.

Segmentation

By Type

The market is categorized into artificial insemination and in-vitro fertilization (IVF). In 2022, the in-vitro fertilization (IVF) segment accounted for the highest revenue share. The segment is further divided by IVF into four categories including frozen non-donor, frozen donor, fresh non-donor, and fresh donor. In 2022, the frozen non-donor segment retained a sizable revenue share. The expansion is due to the advantages of frozen non-donor IVF over conventional IVF techniques. When a woman is releasing viable eggs while receiving ART for male infertility or a fallopian tube abnormality, the frozen non-donor technique is used. The artificial insemination segment is anticipated to have the quickest CAGR during the projection period. According to the Human Fertilization and Embryology Authority (HFEA), the success rates for artificial insemination per individual cycle are approximately 15.8% for women under 35, 11% for women in the 35–39 age group, and 4.7% for women in the 40–42 age group.

By End User

The market is categorized into hospitals & others and fertility clinics & other facilities. In the global market, the fertility clinics & other facilities segment accounted for the largest revenue share in 2022 owing to increase in infertility cases and the demand for a specialised setting to carry out ART. For instance, in May 2021, the West Asian-based Gulf Capitals ART Fertility Facilities announced plans to invest USD 31.3 million in the construction of 18 clinics in important Indian cities by 2023. Cost-effectiveness, specialization, domain knowledge, and personalized care are further factors that are projected to fuel segment growth throughout the course of the projection period. Multispecialty hospitals have emerged as the most practical alternative for the treatment of infertility due to a lack of infrastructure for fertility clinics. As a result, the hospitals and other settings end-use segment is predicted to experience profitable growth in low- and middle-income nations.

Regional Markets

In 2022, Europe region accounted for the highest revenue in the assisted reproductive technology market and is expected to maintain its dominance during the forecast period. This is attributed to increase in the infertility rates, greater knowledge of fertility treatments, developments in technology, and supporting government programmes. For instance, the European Union’s population of almost 25 million, which is the highest number worldwide, suffers from infertility, according to the European Society of Human Reproduction and Embryology. North America is anticipated to exhibit significant expansion during the projection period. The growth is related to the favourable results experienced by patients receiving treatment. According to the CDC2.1% of babies are born in the United States using ART, with the highest percentage occurring in Massachusetts (5.5%), followed by the District of Columbia (5.0%), and New Jersey (4.4%).

Competitor Insights

Some of the key players operating in the assisted reproductive technology market are Microm U.K. Ltd., Parallabs, Origio (CooperSurgical), Cryolab Ltd., Vitrolife AB, Cosmos Biomedical, European Sperm Bank, Irvine Scientific, Ferring B.V., and Bloom IVF Centre.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, CooperSurgical obtained Embryo Options, a well-known provider of cryo-storage software for IVF clinics, in January 2021. Patients will benefit from Embryo Options platform by having access to its online resources, which will inform them about stored specimens for next ART treatment cycles.
• For instance, in July 2021, IVFTECH ApS (IVFtech) and its related company, K4 Technology ApS, were acquired by Hamilton Throne Ltd., a global provider of ART research.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type and end user from 2022 to 2033.

Report Scope:

Segmentation: Assisted Reproductive Technology Market Report 2022 – 2033

Type (Revenue, USD Million), 2022 – 2033

• Artificial Insemination
  • Intracervical Insemination
  • Intratubal Insemination
  • Intrauterine Insemination
  • Intravaginal Insemination
• In-vitro Fertilization
  • Frozen Donor
  • Fresh Donor
  • Frozen Non-Donor
  • Fresh Non-Donor

End user (Revenue, USD Million), 2022 – 2033

• Hospitals & Others
• Fertility Clinics & Other Facilities

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA